Abstract
The natriuretic peptide system includes three known peptides: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). They contribute to the regulation of cardiovascular homeostasis through diuretic, natriuretic, and vasodilatory properties. Among them, ANP has received particular attention because of its effects on blood pressure regulation and cardiac function. Although the potential for its therapeutic application in the treatment of hypertension and heart failure has been evaluated in several experimental and clinical investigations, no pharmacological approach directly targeted at modulation of ANP levels has ever reached the stage of being incorporated into clinical practice. Recently, ANP has also received attention as being a possible cardiovascular risk factor, particularly in the context of hypertension, stroke, obesity, and metabolic syndrome. Abnormalities in either peptide levels or peptide structure are thought to underlie its implied role in mediating cardiovascular diseases. Meanwhile, BNP has emerged as a relevant marker of left ventricular (LV) dysfunction and as a useful predictor of future outcome in patients with heart failure. This review deals with the major relevant findings related to the cardiovascular and metabolic effects of natriuretic peptides, to their potential therapeutic use, and to their role in mediating cardiovascular diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 733-741 |
| Number of pages | 9 |
| Journal | American Journal of Hypertension |
| Volume | 21 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2008 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Natriuretic peptides : An update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. / Rubattu, Speranza; Sciarretta, Sebastiano; Valenti, Valentina; Stanzione, Rosita; Volpe, Massimo.
In: American Journal of Hypertension, Vol. 21, No. 7, 07.2008, p. 733-741.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Natriuretic peptides
T2 - An update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases
AU - Rubattu, Speranza
AU - Sciarretta, Sebastiano
AU - Valenti, Valentina
AU - Stanzione, Rosita
AU - Volpe, Massimo
PY - 2008/7
Y1 - 2008/7
N2 - The natriuretic peptide system includes three known peptides: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). They contribute to the regulation of cardiovascular homeostasis through diuretic, natriuretic, and vasodilatory properties. Among them, ANP has received particular attention because of its effects on blood pressure regulation and cardiac function. Although the potential for its therapeutic application in the treatment of hypertension and heart failure has been evaluated in several experimental and clinical investigations, no pharmacological approach directly targeted at modulation of ANP levels has ever reached the stage of being incorporated into clinical practice. Recently, ANP has also received attention as being a possible cardiovascular risk factor, particularly in the context of hypertension, stroke, obesity, and metabolic syndrome. Abnormalities in either peptide levels or peptide structure are thought to underlie its implied role in mediating cardiovascular diseases. Meanwhile, BNP has emerged as a relevant marker of left ventricular (LV) dysfunction and as a useful predictor of future outcome in patients with heart failure. This review deals with the major relevant findings related to the cardiovascular and metabolic effects of natriuretic peptides, to their potential therapeutic use, and to their role in mediating cardiovascular diseases.
AB - The natriuretic peptide system includes three known peptides: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). They contribute to the regulation of cardiovascular homeostasis through diuretic, natriuretic, and vasodilatory properties. Among them, ANP has received particular attention because of its effects on blood pressure regulation and cardiac function. Although the potential for its therapeutic application in the treatment of hypertension and heart failure has been evaluated in several experimental and clinical investigations, no pharmacological approach directly targeted at modulation of ANP levels has ever reached the stage of being incorporated into clinical practice. Recently, ANP has also received attention as being a possible cardiovascular risk factor, particularly in the context of hypertension, stroke, obesity, and metabolic syndrome. Abnormalities in either peptide levels or peptide structure are thought to underlie its implied role in mediating cardiovascular diseases. Meanwhile, BNP has emerged as a relevant marker of left ventricular (LV) dysfunction and as a useful predictor of future outcome in patients with heart failure. This review deals with the major relevant findings related to the cardiovascular and metabolic effects of natriuretic peptides, to their potential therapeutic use, and to their role in mediating cardiovascular diseases.
UR - http://www.scopus.com/inward/record.url?scp=46249090767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46249090767&partnerID=8YFLogxK
U2 - 10.1038/ajh.2008.174
DO - 10.1038/ajh.2008.174
M3 - Article
C2 - 18464748
AN - SCOPUS:46249090767
VL - 21
SP - 733
EP - 741
JO - American Journal of Hypertension
JF - American Journal of Hypertension
SN - 0895-7061
IS - 7
ER -